Work

Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors

Year: 2019

Type: conference-abstract

Source: Cancer Immunology Research

DOI: 10.1158/2326-6074.cricimteatiaacr18-a006

Authors: Margaret K. Callahan, Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, Andrew Park, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok

Institutions: University of Toledo Medical Center, Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Yale Cancer Center, Mary Crowley Cancer Research Center, Dana-Farber Cancer Institute, Ludwig Cancer Research, University of Virginia

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2913438487

Cites:

Cited by: 1

Related to: 10